Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBITDA: 2020-2025

Historic EBITDA for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$7.0 million.

  • Oncology Institute's EBITDA rose 4600.47% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.1 million, marking a year-over-year increase of 3854.72%. This contributed to the annual value of -$56.9 million for FY2024, which is 2323.27% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's EBITDA is -$7.0 million, which was up 4600.47% from -$10.2 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's EBITDA ranged from a high of -$943000.0 in Q2 2021 and a low of -$40.6 million during Q4 2021
  • For the 5-year period, Oncology Institute's EBITDA averaged around -$14.9 million, with its median value being -$14.3 million (2023).
  • As far as peak fluctuations go, Oncology Institute's EBITDA tumbled by 180296.92% in 2022, and later skyrocketed by 4842.67% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's EBITDA stood at -$40.6 million in 2021, then surged by 39.32% to -$24.6 million in 2022, then soared by 41.18% to -$14.5 million in 2023, then increased by 24.06% to -$11.0 million in 2024, then soared by 35.9% to -$7.0 million in 2025.
  • Its EBITDA stands at -$7.0 million for Q3 2025, versus -$10.2 million for Q2 2025 and -$8.9 million for Q1 2025.